Dr Reddy's climbs 8% on nod for generic Suboxone

NEW DELHI: Shares of Dr Reddy’s Laboratories jumped over 8 per cent in Wednesday’s after the drug maker said the United States Court of Appeals for the Federal Circuit issued a decision in favor of the company.

In June, the USFDA had approved Dr Reddy's Buprenorphine and Naloxone Sublingual Film, in four strengths for sale in the US market. The product was launched immediately after approval. But the sales and commercialisation activities halted as a result of a court-imposed temporary restraining order (TRO) against the company.

The stock rose 8.21 per cent to hit a high of Rs 2,651.50 on BSE.


“The decision vacates the District Court's preliminary injunction that had prohibited Dr Reddy's from selling its generic version of Suboxone (buprenorphine and naloxone) sublingual film. As a result, Dr. Reddy's will resume its launch activities as soon as permitted,” the company said.

A company spokesperson stated, "The decision of the appellate court in Dr Reddy's favor, vacating the preliminary injunction that had prevented Dr Reddy's from bringing this important drug to the public.”